43results about How to "Inhibition of pathogenicity" patented technology

The invention provides an immunogenic molecular entity, a supramolecular assembly, and an antibody that can be used to inhibit Gram-positive bacterial quorum sensing, prevent infection or development of a disease condition associated with a Gram-positive bacterial infection. The invention also provides methods of inhibiting Gram-positive bacterial quorum sensing, and methods of preventing infection or development of a disease condition associated with a Gram-positive bacterial infection.

The invention provides a compound sanguinarine and its anti-rice blast function. The compound exists in the rhizome of Papaveraceae Sanguinarum, and is a natural alkaloid with antibacterial, anti-inflammatory and anti-oxidative properties. Inhibit tumor cell proliferation and promote apoptosis. The present invention detects its effects on the mycelial growth, spore germination, appressorium development and pathogenicity of Magnaporthe grisea by adding sanguinarine compounds in vitro, and the results show that adding a certain concentration of sanguinarine from exogenous sources can effectively activate rice disease resistance-related genes expression, thereby significantly inhibiting the virulence of Magnaporthe grisea. The invention proposes the inhibitory effect of sanguinarine on the pathogenicity of rice blast fungus, indicating that the compound can be used for preventing and treating rice blast.

The invention relates to the use of an adsorbent to reduce or suppress the pathogenicity or virulence of Clostridium bacteria in vitro, ex vivo or in vivo. The invention may be used in any mammal or environment, and is particularly effective to suppress the pathogenicity or virulence of Clostridium difficile.

The invention belongs to the field of biomedicines and in particular relates to a compound for preventing and controlling candida albicans as well as a preparation method and application thereof. Thecompound provided by the invention is 3-methyl-N-(2'-phenemyl)butyramide; an actinomyces streptomyces olivaceus SCSIO T05deltarsdK2 / deltaxmcP mutant strain is constructed through in-frame deletion; amplified fermentation is carried out through a mutant strain fermentation tank, and bacterium collection and centrifuging are carried out; part of mycelia are subjected to ultrasonic extraction throughacetone and part of supernatant is extracted through butanone; extract is combined according to an HPLC (High Performance Liquid Chromatography) analysis result; the compound is obtained by separating through various column chromatography methods. Compared with the prior art, the compound provided by the invention has the beneficial effects that the technology disclosed by the invention successfully prepares and screens the compound 3-methyl-N-(2'-phenemyl)butyramide which has the effects of inhibiting the adhesion of the candida albicans, the mycelium shape transformation and the pathogenicity; meanwhile, the compound 3-methyl-N-(2'-phenemyl)butyramide has relatively small toxicity, does not influence the growth of the candida albicans and human cells and is hopeful to promote and propelthe development of treatment of novel anti-fungus medicines.

The invention aims to disclose the application of allicveratrine in the preparation of medicines for preventing and treating Candida albicans infection. Through the detection of various indicators such as the effect of the compound allicveratrine on the growth of Candida albicans, mycelia inhibition rate, cytotoxicity, and animal models, the results show that allicveratrine has no obvious effect on the growth of Candida albicans, among which, The compound allicilveratrine can still effectively inhibit the mycelium formation of Candida albicans when the concentration is 50 μM, and the mycelium formation rate is lower than 50%. In addition, allicveratrine has a good protective effect on human cell A549 infected by Candida albicans, and the compound allicveratrine itself has no obvious toxic and side effects on cells. In the mouse oral model, garlic veratrine has a good inhibitory effect on the invasion of Candida albicans.

A pharmaceutical composition comprising at least 0.1 μmol of formaurindicarboxylic acid or its derivatives in 1 kg of pharmaceutically acceptable carrier. The pharmaceutical composition of claim 1 wherein the composition is in the form of solution prepared using aqueous alcali or water.

The invention belongs to the technical field of biomedicines and in particular relates to a 2-alkylamine quinoline compound for preventing and treating candida albicans as well as a preparation methodand application of the 2-alkylamine quinoline compound. The compound is prepared from a compound A (1,2,3,4-Tetrahydroquinolines) and a compound B (O-benzoyl hydroxylamines) as raw materials throughsynthesis. Compared with the prior art, the compound has the advantages and effects that results of former research of the inventor show that a diffusible signal factor (DSF) quorum sensing signal anda derivative thereof are capable of relatively intensely interfering conversion of a yeast state to a hypha state of candida albicans, and the compound capable of inhibiting adhesion, hypha state conversion and pathogenicity of the candida albicans is successfully synthesized and screened in the research. Meanwhile, the compound is relatively small in toxicity, growth of the candida albicans andhuman cells is not affected, and the characteristics have the potential of promoting development of novel antifungal drugs.

The invention discloses an R.solani AG1-IA pathogenic related gene and application thereof. The invention provides the R.solani AG1-IA pathogenic related gene and a silent target gene segment Rstpp ofthe R.solani AG1-IA pathogenic related gene. By taking the segment as a target, the pathogenic related genes can be silenced, so that the pathogenicity of R.solani AG1-IA is remarkably inhibited. ThedsRNA of the silent target gene segment Rstpp can be used for preparing a product for preventing and treating R.solani AG1-IA. On the basis, the invention also provides a recombinant vector constructed by using dsRNA. The recombinant vector can be transformed to a plant, and the obtained transgenic plant has obvious disease resistance to R.solani AG1-IA. Therefore, the R.solani AG1-IA pathogenicrelated gene and the silent target gene segment Rstpp thereof have wide popularization and application prospects in prevention and treatment of R.solani AG1-IA including construction of R.solani AG1-IA resistance transgenic plants.